Get the complete picture – the intersection of legal, regulatory and commercial strategies for the innovator and biosimilars marketplace.

September 2020 will mark the 11th time that the “who’s who” of the biosimilars industry will gather for ACI’s Annual Summit on Biosimilars.

The novel coronavirus instigated arguably the most important patent story of the year, as COVID-19 ushered in unforeseen challenges for the biosimilars and innovator biologics industries. While patent approvals stalled during the global pandemic, the pipeline continued to grow.

Even so, the conventional barriers remain, such as lack of familiarity and education that influence the use of biosimilars. Now, more than ever, strategies to overcome these barriers are vital to expand the awareness and understanding of these products in the United States. The need for a solid guiding framework has become more critical than ever before.

This September, join top practitioners and industry thought leaders from the biosimilars and innovator biologics communities as they convene for ACI’s 2020 Summit on Biosimilars & Innovator Biologics, and examine the impact of these critical developments while carving out a path forward.

See Who Attended in the Past
  • Acceleron Pharma Inc
  • Aceto Corporation
  • Acorda Therapeutics Inc
  • Actavis Generics
  • ALDER BIOPHARMACEUTICALS
  • Alexion Pharmaceuticals Inc
  • Allergan
  • Amgen
  • AMRI Inc
  • Apotex Corporation
  • Association for Accessible
  • Medicines
  • Athersys Inc
  • Baker Bros. Advisors LP
  • Barr Laboratories
  • Bausch & Lomb Inc
  • Baxter Healthcare Corp
  • Bayer HealthCare LLC
  • Bedford Laboratories
  • Ben Venue Laboratories
  • Biogen
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Brattle Group
  • BRM Biopharm Source LLC
  • Celgene Corporation
  • Centocor Inc
  • Cerulean Pharma Inc
  • Chemo Espana
  • ChemWerth Inc
  • Coherus Biosciences Inc
  • Cornerstone Research
  • Daiichi Sankyo Co Ltd
  • DaVinci Healthcare
  • Dr. Reddy’s Laboratories
  • Duke University Fuqua School of
  • Business
  • Eisai Co Ltd
  • Elan Pharmaceuticals Inc
  • Eli Lilly & Company
  • EMD Serono Inc
  • Endo Pharmaceuticals Inc
  • Ernest Mario School of Pharmacy
  • Fresenius Kabi Deutschland GmbH
  • Gedeon Richter Pharma GmbH
  • Gene Techno Science Co Ltd
  • Genentech
  • Genzyme
  • Gilead Sciences
  • Glaxosmithkline Plc
  • Glycobia
  • GSK
  • GTC Biotherapeutics Inc
  • Hoffmann-La Roche
  • Hospira Inc
  • ImClone Systems Incorporated
  • Immunogen Inc
  • Johnson & Johnson
  • LG Life Sciences
  • Lonza
  • Lupin Pharmaceuticals Inc
  • Medicago Inc
  • Medicines Company
  • MedImmune Inc AstraZeneca
  • Merck & Co
  • Millennium Pharmaceuticals Inc
  • Momenta Pharmaceuticals Inc
  • Mylan
  • National Institute of Allergy &
  • Infectious Diseases
  • Navigators Insurance
  • Neose Technologies Inc
  • Novartis Oncology
  • Novo Nordisk
  • Paravid LLC
  • PDL Biopharma Inc
  • Pfizer Inc
  • PhRMA
  • Purdue Pharma LP
  • R-T Specialty LLC
  • Regeneron Pharmaceuticals Inc
  • Roche Inc
  • Samsung Bioepis Co Ltd
  • Sanofi
  • Seattle Genetics Inc.
  • Shionogi & Co Ltd
  • Shire Pharmaceuticals
  • Sunovion Pharmaceuticals Inc
  • Sutro Biopharma Inc
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical
  • UCB Inc
  • Vertical Pharmaceuticals Inc
  • Wyeth BioPharma
  • Zydus Research Centre